Advaxis Submits Investigational New Drug Application for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Advaxis Submits Investigational New Drug Application for ADXS31-142 (ADXS-PSA) for the Treatment of Metastatic Castration Resistant Prostate Cancer

PRINCETON, N.J., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS ), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the Company has submitted an Investigational New Drug application (IND) to the United States Food and Drug Administration (FDA) to conduct the first-in-human study of ADXS31-142 for the treatment of metastatic castration resistant prostate cancer (mCRPC). ADXS31-142 is Advaxis's lead Lm -LLO immunotherapy designed to specifically target prostate-specific antigen (PSA).

Pending FDA's acceptance of the IND submission, the proposed Phase 1/2 protocol is designed to evaluate the safety and efficacy of ADXS31-142 as monotherapy and in combination with KEYTRUDA ® (pembrolizumab), the first anti-PD-1 (programmed death receptor-1) therapy approved in the United States, by Merck, known as MSD outside the United States and Canada, through its subsidiaries.

The Phase 1 part of the trial is designed to identify a recommended dose for ADXS31-142 when used alone and when combined with KEYTRUDA. The Phase 2 part of the trial will assess the safety and efficacy of the combination regimen. Advaxis and Merck will collaboratively oversee the conduct of the study, which is planned to begin in early 2015. Results from the open-label study will be used to determine the future clinical development program for the combination.

Within 30 calendar days of the IND filing, FDA will notify Advaxis of any questions it has or protocol revisions it requests which may delay this timing. Advaxis plans to work with the FDA review team to address any questions or requests that arise within this 30-day window.

"With the filing of our ADXS31-142 IND, we are on track to begin a Phase 1/2 human clinical trial with a second Lm -LLO immunotherapy investigational new drug in early 2015," commented Daniel J. O'Connor, President and Chief Executive Officer of Advaxis. "This is another important milestone for Advaxis as we continue to advance our pipeline of immunotherapy candidates and investigate novel combinations with checkpoint inhibitors and other synergistic agents that we believe may offer new treatment options for patients with cancer."

Both ADXS31-142 and KEYTRUDA are members of a new class of cancer treatments known as immunotherapies, which are designed to enhance the body's own defenses in fighting cancer. Data from preclinical studies suggest that Advaxis Lm -LLO immunotherapies in combination with a PD-1 inhibitor may lead to an enhanced anti-tumor immune response. The goal of the Phase 1/2 trial is to begin examining that potential.

About Prostate Cancer

Prostate cancer is the second most common form of cancer affecting men in the United States: an estimated one in six will be diagnosed with prostate cancer in his lifetime. The American Cancer Society estimates that approximately 233,000 new cases of prostate cancer will be diagnosed and about 30,000 men are expected to die of the disease this year.

About ADXS-PSA

ADXS-PSA is an Lm -LLO immunotherapy that is designed to target the prostate-specific antigen (PSA), a protein produced exclusively by prostate cells that is associated with prostate cancer. ADXS-PSA secretes the PSA antigen, fused to the powerful immunostimulant tLLO, directly inside the antigen presenting cells that are capable of driving a cellular immune response to PSA expressing cells. This approach is also designed to inhibit the Treg and myeloid-derived suppressor cells (MDSCs) that contribute to immunologic tolerance of prostate cancer. In preclinical analysis, ADXS-PSA inhibits the immunosuppression caused by Treg and MDSC cells localized inside tumors that may promote immunologic tolerance of prostate cancer.

About Advaxis, Inc.

Advaxis is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm -LLO platform technology. The Lm -LLO technology, using bioengineered live attenuated Listeria monocytogenes bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and myeloid-derived suppressor cells (MDSCs), that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis's lead Lm -LLO immunotherapy, ADXS-HPV, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The FDA has granted Advaxis orphan drug designation for each of these three indications. The Company plans to initiate a registrational clinical program for cervical cancer in 2015 and has established licensing partners in India and Asia for commercialization in those regions. Advaxis entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, for a Phase 1/2 immunotherapy study to evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis's ADXS-HPV as a treatment for patients with advanced, recurrent or refractory HPV-associated cervical cancer and HPV-associated head and neck cancer.

Advaxis's second Lm -LLO immunotherapy candidate in clinical testing will be ADXS-PSA, which is being developed to address prostate cancer. Advaxis entered into a clinical trial collaboration agreement with Merck & Co., Inc. ("Merck"), known as MSD outside the United States and Canada, through its subsidiaries, to evaluate the combination of Advaxis's Lm -LLO cancer immunotherapy, ADXS-PSA, with Merck's PD-1 checkpoint inhibitor KEYTRUDA ® (pembrolizumab). The planned clinical trial will evaluate the safety and efficacy of ADXS-PSA as monotherapy and in combination with pembrolizumab in a Phase 1/2 study of patients with previously treated metastatic, castration-resistant prostate cancer.

Advaxis is also developing Lm -LLO immunotherapy ADXS-cHER2, to target the Her2 receptor overexpressing cancers. Her2 is overexpressed in certain solid-tumor cancers, including pediatric bone cancer (or osteosarcoma), breast cancer, esophageal, and gastric cancer. ADXS-cHER2 has received orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of osteosarcoma. Advaxis is developing ADXS-cHER2 for both human and animal-health, and has seen promising results in canine osteosarcoma, which is considered a model for human osteosarcoma. Advaxis is planning to file an IND for ADXS-cHER2 in Her2 overexpressing cancers and to conduct a clinical program in pediatric osteosarcoma. Advaxis has licensed ADXS-cHER2 and three other immunotherapy constructs to Aratana Therapeutics, Inc. for pet therapeutics.

For more information please visit www.advaxis.com .

Forward-Looking Statements

This news release contains forward-looking statements, including, but not limited to: statements regarding Advaxis's ability to develop the next generation of cancer immunotherapies; the safety and efficacy of Advaxis's proprietary immunotherapy, ADXS HPV; whether Advaxis immunotherapies can redirect the powerful immune response all human beings have to the bacterium to cancers. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis's SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2013, which is available at http://www.sec.gov . Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

KEYTRUDA is a registered trademark of Merck & Co., Inc.

Company: Advaxis, Inc. Greg Mayes, Executive Vice President and COO 609.452.9813 ext. 102 Media Contact: Tiberend Strategic Advisors, Inc. Amy S. Wheeler 646.362.5750

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SAGA's Radar Assays Tighten the Trapper North Case

Updated Category News Views 22

Rock that keeps showing up where the model says it should is the sort of boring news a junior miner desperately needs. SAGA Metals has put out fresh assay results from Radar’s Trapper North area, and the useful part is not merely a loud grade in one hole. It is the apparent persistence of thick titanium-vanadium-iron oxide mineralization across tighter-spaced drilling....

Continue Reading
Disney Springs Hotel Rates Test Holiday Demand Depth

Updated Category News Views 20

A $145 room rate is the sort of holiday bait that gets my attention before the fake snow does. Disney Springs Resort Area Hotels are extending a seasonal offer for stays through Dec. 18, 2026, with bookings open only through Nov. 20. That is a very narrow selling window, and it tells you plenty: these seven independent hotels want to fill rooms during a lucrative but...

Continue Reading
Yoodli's No. 9 Ranking Signals Enterprise AI Traction

Updated Category News Views 0

Ninth place can be easy to dismiss until you notice the company is sitting near the top of a 500-name growth list. Yoodli's No. 9 position on Deloitte's 2026 Technology Fast 500 is a meaningful signal that its AI-based coaching and workforce-skills pitch is getting traction inside large organizations. It is not a revenue disclosure, it is not a valuation marker, and...

Continue Reading
Workday’s EU Cloud Move Raises the Sovereignty Bar Again

Updated Category News Views 60

Europe’s sovereignty squeeze just got a lot more concrete for Workday. The company is taking its EU Sovereign Cloud beyond the usual data-residency talking points by planning an Ireland-based operating company, European leadership, and governance intended to keep decisions on the service and customer data inside Europe. For a platform sitting underneath payroll, HR...

Continue Reading
Halff Elevates People and Delivery Leadership Team

Updated Category News Views 78

Infrastructure outfits rarely make much noise when they reshuffle leadership, but Halff’s Nov. 18 announcement deserves a closer look than the usual executive-title confetti. The employee-owned consulting firm has put Greg Carpenter in the chief people officer seat and named Leigh Hollis chief delivery officer. One role is aimed squarely at the human machinery; the...

Continue Reading
LASIK Cost Math Deserves a Careful Second Look Today

Updated Category News Views 204

Thirty years of lens purchases can become a nasty tab Contact-lens spending has a funny way of staying invisible until somebody stacks the receipts into one ugly pile. A new cost-of-vision analysis from the surgeon advisory board of BestLASIKSurgeons.com says the average American contact-lens wearer may spend between $22,500 and $30,000 on corrective eyewear across 30...

Continue Reading
Clorox Boosts Payout With Steady $1.25 Dividend

Updated Category News Views 221

Quarterly Dividends: A Clorox Tradition It seems you can't talk about Clorox (NYSE: CLX) without mentioning its steadfast dedication to shareholders. Once again, this 113-year-old stalwart is back on the map with its juicy quarterly dividend—$1.25 per share, to be precise. That's scheduled to hit your account by February 12, 2027, if you're on the books by the end of...

Continue Reading
Teachers in Space Takes Its Classroom Model Orbital

Updated Category News Views 0

Two teachers strapped into a research flight may sound like a glossy space-age photo op, but the useful part of this plan sits back in the classroom with the students staring at the data. Teachers in Space wants to send two educators aboard a Virgin Galactic research flight expected in 2027, and it is raising $2 million to fund the broader educational program and mission....

Continue Reading
Yatsen’s November 25 Report Is the Real Beauty Test

Updated Category News Views 46

Beauty shelves can hide a lot of sins, but earnings day tends to drag them into fluorescent light. Yatsen will release unaudited third-quarter 2026 financial results before the U.S. market opens on Wednesday, November 25, then management will take questions at 7:30 a.m. Eastern Time. For anyone following NYSE:YSG, this is not a results story yet. It is a calendar marker,...

Continue Reading
ActivTrak's Fast 500 Rank Needs Investor Perspective

Updated Category News Views 27

Rank 488 is the sort of trophy that deserves a raised eyebrow, not confetti. ActivTrak made Deloitte's 2026 Technology Fast 500 after posting 101.1% revenue growth from 2022 through 2025, its sixth appearance on the list since 2020. That is real progress, and repeat recognition says this was not a one-quarter sugar high. Still, a Fast 500 ranking is a growth screen, not a...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring AML's Innovative Permanent Magnet Manufacturing

Updated Category News Views 246

Revolutionizing Permanent Magnet Production Advanced Magnet Lab, Inc. (AML) has emerged as a frontrunner in the field of innovative magnet technologies. By harnessing their advanced PM-Wire™ manufacturing process, AML is setting the stage for a broad range of applications that require permanent magnets. This new technology opens avenues for diverse supply chain...

Continue Reading
Harmonic Secures $75 Million Funding to Innovate AI Mathematics

Updated Category News Views 475

Harmonic Secures $75 Million in Series A Funding Harmonic, a Palo Alto-based innovator in artificial intelligence, has just revealed that it successfully raised $75 million in a Series A funding round. This investment values the company at $325 million, led by the well-known venture capital firm Sequoia Capital, alongside significant backing from Index Ventures and...

Continue Reading
Peoria's Mercedes-Benz of Arrowhead Offers Luxury 3-Row SUVs

Updated Category News Views 22

Luxury SUVs with Space and Sophistication When it comes to racking up the mileage in style, finding that sweet spot between luxury and practicality is the holy grail for many car buyers. Right in the heart of Peoria, Arizona, Mercedes-Benz of Arrowhead is rolling out a red carpet for those of us who crave both opulence and utility in one sleek package. Why Third-Row...

Continue Reading
Understanding the Rise in Comfort Systems USA's Short Interest

Updated Category News Views 176

Understanding Comfort Systems USA's Short Interest The short interest of Comfort Systems USA (NYSE: FIX) has seen a notable rise, increasing by 40.65% since the last report. This reflects growing concerns or speculation surrounding the company's stock performance. Currently, approximately 536 thousand shares are sold short, which constitutes 2.18% of the total shares...

Continue Reading
Investigating Today's Top 5 Stocks: Trends and Insights

Updated Category News Views 181

Market Overview Stocks in the U.S. presented a mixed picture recently, with notable fluctuations in the major indexes. The Dow Jones Industrial Average saw a slight dip of 0.1%, closing at 44,837.56, while the S&P 500 remained stable at 6,389.77. Meanwhile, the Nasdaq climbed slightly, gaining 0.3% to end the day at 21,178.58. Top Five Stocks to Watch Today Market...

Continue Reading